• Contact
  • Important Safety Information
  • Prescribing Information
  • Healthcare Professionals
Iluvien Logo
  • About Diabetic
    Macular Edema
    • What is Diabetic Macular Edema?
    • Symptoms of DME
    • Getting a DME diagnosis
    • What are my treatment options?
  • ILUVIEN for DME
    • What is ILUVIEN?
    • ILUVIEN Injection Procedure
    • ILUVIEN Safety
  • What to Expect
    • Your ILUVIEN Journey
    • Patient Stories
    • Find Your ILUVIEN Doctor
  • Resources
    • Financial Assistance
    • Caregiver Tips
    • Glossary
    • Educational Blog
Find Your ILUVIEN Doctor
  • Contact
  • Important Safety Information
  • Prescribing Information
  • Healthcare Professionals
Indication and Important Safety Information

Indication

Indication: ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Important Safety Information

  • Do not use ILUVIEN if you have or think you might have an infection in or around the eye.
  • ILUVIEN should not be used if you have glaucoma with a cup to disc ratio of greater than 0.8.
  • You should not use ILUVIEN if you have a hypersensitivity to any components of this product.
  • Injections into the vitreous in the eye are associated with a serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, glaucoma, and retinal detachments. Your eye doctor should monitor you regularly after the injection.
  • Corticosteroids may increase secondary eye infections due to bacteria, fungi, or viruses. Let your doctor know if you have a history of herpes viral infections of the eye.
  • If the posterior capsule of the lens of your eye is missing or torn, the ILUVIEN implant may move to the front chamber of the eye.
  • The most common side effects reported in patients with diabetic macular edema who were treated with corticosteroids, including ILUVIEN, include cataracts (ILUVIEN 82%; sham 50%) and increased eye pressure (ILUVIEN 34%; sham 10%).
  • This safety information is not comprehensive. For additional safety information, please talk to your doctor and see the full Prescribing Information for ILUVIEN at iluvien.com.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Alimera Logo
  • Terms & Conditions
  • Privacy Policy
  • Contact Us
  • Your ILUVIEN Journey

This site is intended for US residents only. ILUVIEN is a registered trademark of Alimera Sciences, Inc.
CONTINUOUS MICRODOSING and the CONTINUOUS MICRODOSING symbol are trademarks of Alimera Sciences, Inc.
Copyright © 2022 Alimera Sciences, Inc. All rights reserved. 1-844-445-8843. US-ILV-MMM-0029

Possible Questions to Ask your Doctor:

  • How does my diabetes affect DME?
  • How might DME impact my life?
  • Are there steps I can take to help slow the progression of DME?
Download a PDF with more questions

  • Get helpful information delivered right to your inbox!

    Learn about the benefits of ILUVIEN, inspiring patient stories, financial assistance and more. We will keep emails to a minimum and only send you relevant, useful information!

  • Field is Required.
  • Field is Required.
  • Please select one. Field is Required.
  • Field is required.

  • Share Iluvien with someone you love

  • You can edit this message! Be sure to replace [FIRST NAME] with your recipient's name, and [YOUR NAME] in the message closing so they know it is from you.

  • Don’t worry! We will not save any email addresses. This only sends a one-time email.

  • This field is for validation purposes and should be left unchanged.